Novo Nordisk AS (XTER:NOV) Net Interest Margin (Bank Only) %


XTER:NOV Novo Nordisk AS XTER:NOV
65 GF Score
Price €43.13
GF Value €121.06
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

XTER:NOV
65GF Score
Novo Nordisk AS XTER:NOV
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (XTER:NOV) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.13 is trading 64.4% below its estimated GF Value™ of €121.06. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for XTER:NOV:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €121.06 vs. price of €43.13 (64.4% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the XTER:NOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
65GF Score

Get the complete analysis for XTER:NOV

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.13
Price
€121.06
GF Value